BJP Evidence-Based Mental Health
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Poyurovsky, M.
Right arrow Articles by Weizman, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Poyurovsky, M.
Right arrow Articles by Weizman, A.

The British Journal of Psychiatry 174: 238-242 (1999)
© 1999 The Royal College of Psychiatrists

Treatment of neuroleptic-induced akathisia with the 5-HT2 antagonist mianserin. Double-blind, placebo-controlled study

M Poyurovsky, M Shardorodsky, C Fuchs, M Schneidman and A Weizman
Research Unit, Tirat Carmel Mental Health Center, Israel.

BACKGROUND: Serotonin (5-HT):dopamine imbalance may underlie neuroleptic-induced akathisia. AIM: To evaluate the efficacy of the 5- HT2 antagonist, mianserin in neuroleptic-induced akathisia. METHODS: Thirty neuroleptic-treated patients with schizophrenia were randomly allocated in a double-blind design to receive either mianserin (15 mg/day) or placebo for five days. Patients were assessed at baseline and on Days 3 and 5 by the Barnes Akathisia Scale (BARS), as well as by other relevant clinical rating scales. RESULTS: Compared with the placebo group, the mianserin-treated patients showed a significant reduction in all four BARS subscales by Day 5, with mean reductions in the BARS global score of 9.9% and 52.2%, respectively (P = 0.006). Response to treatment (a reduction of at least two points on the BARS global subscale), was noted in six patients (40%) in the mianserin group and only one patient (9.1%) in the placebo group (P = 0.04, log odds ratio 2.23). CONCLUSIONS: Mianserin at a low dose may be a promising therapeutic option for patients with acute neuroleptic- induced akathisia.


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
R. Hieber, T. Dellenbaugh, and L. A. Nelson
Role of Mirtazapine in the Treatment of Antipsychotic-Induced Akathisia
Ann. Pharmacother., June 1, 2008; 42(6): 841 - 846.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. Ranjan, P. S Chandra, S. K Chaturvedi, S. C Prabhu, and A. Gupta
Atypical Antipsychotic-Induced Akathisia with Depression: Therapeutic Role of Mirtazapine
Ann. Pharmacother., April 1, 2006; 40(4): 771 - 774.
[Abstract] [Full Text] [PDF]

Home page
 PsychosomaticsHome page
G. Catalano, J. W. Grace, M. C. Catalano, M. J. Morales, and L. M. Cruse
Acute Akathisia Associated With Quetiapine Use
Psychosomatics, August 1, 2005; 46(4): 291 - 301.
[Abstract] [Full Text] [PDF]

Home page
 J. Neuropsychiatry Clin. Neurosi.Home page
K. Tuisku, M. Virkkunen, M. Holi, H. Lauerma, H. Naukkarinen, R. Rimon, and K. Wahlbeck
Antisocial Violent Offenders With Attention Deficit Hyperactivity Disorder Demonstrate Akathisia-Like Hyperactivity in Three-Channel Actometry
J Neuropsychiatry Clin Neurosci, May 1, 2003; 15(2): 194 - 199.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
M. POYUROVSKY and A. WEIZMAN
Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: a new approach to an old problem
The British Journal of Psychiatry, July 1, 2001; 179(1): 4 - 8.
[Full Text] [PDF]

Home page
 Psychiatr. Bull.Home page
I. Maidment
Use of serotonin antagonists in the treatment of neuroleptic-induced akathisia
Psychiatr. Bull., September 1, 2000; 24(9): 348 - 351.
[Full Text]

Home page
 Evid. Based Ment. HealthHome page
Other articles noted
Evid. Based Ment. Health, August 1, 1999; 2(3): 72 - 72.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Psychiatric Bulletin Advances in Psychiatric Treatment All RCPsych Journals
Copyright © 1999 The Royal College of Psychiatrists.